Related Experiment Video

Updated: Dec 24, 2025

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
10:28

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks

Published on: June 26, 2020

10.2K

Effectiveness of Elbasvir/Grazoprevir in US Veterans with Chronic Hepatitis C Virus Genotype 1b Infection

Amy Puenpatom1, Yumei Cao2, Xian Yu2

  • 1Merck & Co., Inc., Kenilworth, NJ, USA. puenpatom.amy@merck.com.

Infectious Diseases and Therapy
|April 17, 2020
PubMed

Insights

Elbasvir/grazoprevir effectively treated chronic hepatitis C virus (HCV) genotype 1b infection in a large group of veterans. High rates of sustained virologic response (SVR) were observed across diverse patient subgroups.

Area of Science:

  • Hepatology
  • Infectious Diseases
  • Pharmacotherapy

Background:

  • Real-world hepatitis C virus (HCV) treatment presents challenges not seen in clinical trials.
  • Assessing elbasvir/grazoprevir efficacy in a diverse patient population is crucial.

Purpose of the Study:

  • To evaluate the effectiveness of elbasvir/grazoprevir for chronic HCV genotype 1b infection.
  • Focus on a large cohort within the Veterans Affairs healthcare system.

Main Methods:

  • Retrospective analysis of patients aged 18+ with HCV genotype 1b.
  • Included patients with at least one prescription of elbasvir/grazoprevir between Feb 2016 and Aug 2017.
  • Primary analysis in the per-protocol population (≥11 weeks treatment, available SVR data).

Main Results:

  • The study included 3371 patients, predominantly male (97.3%) and treatment-experienced (85.5%).
  • High rates of sustained virologic response (SVR) were achieved: 97.5% overall.
  • SVR rates remained high across subgroups, including those with chronic kidney disease, history of drug use, and cirrhosis.

Conclusions:

  • Elbasvir/grazoprevir demonstrated high efficacy in treating HCV genotype 1b in a real-world Veterans Affairs setting.
  • The treatment was effective across various patient demographics and comorbidities.
Abstract

Keywords:
Hepatitis CLiver fibrosisReal-worldVeteransViral hepatitis

More Related Videos

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation08:04

Development of an IFN-γ ELISpot Assay to Assess Varicella-Zoster Virus-specific Cell-mediated Immunity Following Umbilical Cord Blood Transplantation

Published on: July 9, 2014

16.2K
Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

7.3K

Related Concept Videos

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test01:22

Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test

In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
120
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment01:08

Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment

Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
137
Hepatic Drug Excretion: Influencing Factors01:16

Hepatic Drug Excretion: Influencing Factors

The biliary system of the liver, crucial for bile secretion and drug excretion, comprises intrahepatic bile ducts that merge to form the common hepatic duct. This duct, carrying hepatic bile, combines with the cystic duct, draining the gallbladder and forming the common bile duct, which empties into the duodenum. Bile, produced by hepatic cells lining the bile canaliculi, is composed primarily of water, bile salts, pigments, electrolytes, and lesser amounts of cholesterol and fatty acids. Bile...
465
Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug01:14

Effect of Hepatic Disease on Pharmacokinetics: Active Drug, Metabolite and Fraction of Metabolized Drug

In pharmacotherapy, monitoring drug concentrations is paramount, especially for drugs whose therapeutic effects hinge on both the active compound and its metabolite. Hepatic impairment profoundly influences drug potency by altering liver function. If the drug is more potent than its metabolite, impaired liver function amplifies drug activity due to elevated drug concentration levels. Conversely, if the metabolite holds greater potency, diminished liver function diminishes drug activity by...
145
Chronic Pancreatitis II: Collaborative Care01:29

Chronic Pancreatitis II: Collaborative Care

The management of chronic pancreatitis is multifaceted, involving a comprehensive approach that includes thorough assessment, diagnostic testing, and a variety of management strategies.
Assessment:
227
Hepatic Drug Clearance: Effect of Protein Binding01:09

Hepatic Drug Clearance: Effect of Protein Binding

Hepatic clearance is influenced by protein binding based on the drug's extraction ratio. Drugs with high extraction ratios are considered flow-limited and remain unaffected by protein binding during hepatic clearance. On the other hand, drugs with low extraction ratios may be impacted by plasma protein binding, although the extent of this influence depends on the fraction of the drug bound.
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
462